Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates

Aptamer Group Limited, the developer of Optimer™ Therapeutics, and PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, today announce that they have entered into a strategic collaboration agreement. The agreement is to develop Optimer-drug conjugates for targeted drug delivery combining Aptamer Group’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.

Optimer therapeutics are optimized aptamer solutions. Optimer-drug conjugates offer uniquely specific targeting vehicles for the delivery of therapeutic agents to selected cell populations and tissues for the treatment of disease.

PinotBio’s FL-118 payload system is a novel camptothecin based payload to be used in various carrier-drug conjugates, including Optimer-Drug conjugate. FL-118 shows strong anti-cancer effects against various tumor models and at the same time possesses good safety profiles to be developed as a part of the multi-target collaboration.

Aptamer will provide the developed Optimers to PinotBio for use with their payload and linker technologies.  PinotBio will generate and optimize Optimer-drug conjugates against multiple undisclosed targets. Pinotbio will carry out pre-clinical research and development to evaluate each of the Optimer-drug conjugates and their potential to progress as clinical candidates for the treatment of haematological cancers, such as leukaemia, lymphoma, and myeloma.

The commercial terms of the agreement are not disclosed.

I am very excited to have established this collaboration with PinotBio. The development of drug conjugates that combine the benefits of Optimer binders to selectively and efficiently target PinotBio’s novel linker delivery system to the tumour site for activation and therapeutic delivery represents the next evolution is drug delivery technology. We are looking forward to working with the team at PinotBio and believe this collaboration has the potential to develop much-needed improved oncological treatments.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group

I am very excited to begin this collaboration with Aptamer Group Limited. This field of targeted delivery of anti-cancer compounds is fast growing and at the same time fast changing. Combining 3 things, right target, right vehicle, and right payload is equally important. I believe that through this collaboration, we can combine the right vehicle and payload to result in novel drug candidates with a potential to change the cancer treatment landscape.

Dr Doo Young Jung, Chief Executive Officer of PinotBio

  • https://aptamergroup.com/aptamer-and-pinotbio-collaborate-to-develop-new-therapeutic-drug-conjugates/


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Aptamer Group. (2021, June 02). Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates. News-Medical. Retrieved on May 20, 2024 from https://www.news-medical.net/news/20210602/Aptamer-Group-and-PinotBio-collaborate-to-develop-new-therapeutic-drug-conjugates.aspx.

  • MLA

    Aptamer Group. "Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates". News-Medical. 20 May 2024. <https://www.news-medical.net/news/20210602/Aptamer-Group-and-PinotBio-collaborate-to-develop-new-therapeutic-drug-conjugates.aspx>.

  • Chicago

    Aptamer Group. "Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates". News-Medical. https://www.news-medical.net/news/20210602/Aptamer-Group-and-PinotBio-collaborate-to-develop-new-therapeutic-drug-conjugates.aspx. (accessed May 20, 2024).

  • Harvard

    Aptamer Group. 2021. Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates. News-Medical, viewed 20 May 2024, https://www.news-medical.net/news/20210602/Aptamer-Group-and-PinotBio-collaborate-to-develop-new-therapeutic-drug-conjugates.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing